Dimension Inx, a biomaterials platform company, has announced it has closed a $12M Series B Round.
Prime Movers Lab (PML) led the round, with cooperation from returning investors KdT Ventures and Revolution’s Rise of the Rest Seed Fund (ROTR). This round also includes new investors Solas BioVentures and Portal Innovation Ventures. Alumni Ventures is also included. The funds will be employed to accelerate the development of functional organ regeneration therapeutics and to broaden the company’s manufacturing capabilities. The funds will be used to assist in the commercial release of the firm’s first product, CMFlex, in the near future.
Dimension Inx revealed that CMFlex was the first 3D printed bone graft product to be approved by FDA. CMFlex, an easy-to-use, versatile ceramic for oral, maxillo-facial and other indications, improves surgeon workflow and reduces case time while restoring healthy bone.
“Dimension Inx represents the type of breakthrough science we believe will transform their industry and reshape our physical world,” said Prime Movers Lab Venture Partner Amy Kruse, Ph.D. who will be joining the company’s board. “We’re excited to support Dimension Inx as they enter this next phase of growth and development, and bring their transformative products to market.”
“FDA clearance is a major milestone for our platform, and validates the work we’ve put into developing our product over the past two years,” said CEO of Dimension Inx, Caralynn Nowinski Collens, M.D. “CMFlex is a product that represents our unique approach to restoring functionality in the body: it’s a dynamic collaboration between biology, material composition, microstructure, and macro architecture. We’re excited by the interest we’ve already received from surgeons who recognize the importance of a ready-to-use solution that is easy to handle and accelerates healing to improve patient outcomes.”
Tissue, highlighting its unique micro and nano-porosity as well as texture. Image via DimensionInx.
Dimension Inx’s industrial 3D printing portfolio
A team of researchers from Carnegie Mellon University and University of Connecticut (3D printed new calcium phosphate graphene scaffolds. These could be used for bone restoration in the future. Dimension Inx’s Direct Ink Writing (DIW) 3D printing method was used by the team to print porous concepts of its CaPG material with a large weight fraction to allow a “significantly high” graphenic content inside the ink (around 90%). This allowed cellular access to the osteoconductive backbone and the sustained release of phosphate and calcium ions, indicating that the operational graphenic content, instead of the bioinert binder, dominated the host’s response to the matrix.
“We pride ourselves in catalyzing a step function change to unlock the full potential of regenerative therapeutics to cure complex disease, and we’re grateful to do so with the support of our investors,” added Dr. Collens. “Our approach has always focused on the entire tissue microenvironment. If we provide the right blueprint, we make it possible to recruit the body’s natural strengths and accelerate the repair, regeneration, and ultimately, restoration of critical body function.”
Dimension Inx received funding from the US Department of Defense (DoD), which was $240,000 to help build a regenerative medical device capable of treating tracheal injuries. The project used the company’s patented biomaterials platform to produce implantable parts that mimic the tracheal microenvironment and merge them with a novel hydrogel to assist in remodeling into typically functional tracheal tissue.
Series funding rounds for the additive manufacturing sector
Fictiv, a San Francisco-based service provider for on-demand manufacturing services, raised $100 million in Series E funding. This round of funding increased the firm’s total capital raised to about $192 million. Activate Capital led Fictiv’s Series E round, with participation from established institutional investors Accel, Bill Gates, G2 Venture Partners, and Standard Investments. Angeleno Group Cross Creek and Westly Group were added as new investors.
9T Labs, a Swiss carbon fiber 3D printer specialist, raised $17million in Series A funding. This was used to market its Red Series Additive fusion Solution platform. This platform, which combines 3D printers and compression molding, can be used to create advanced carbon fiber-reinforced, thermoplastic composite parts. It is capable of producing 100 to more than 100,000 parts annually. 9T Labs was able, with the support from Stratasys (an industrial 3D printer manufacturer) and other key investors to fully commercialize its platform for producing components for end-use in the aerospace, automotive medical, industrial, consumer goods, and industrial industries.
What is the? Future of 3D printing For the next ten year, what will it be?
What engineering challenges What challenges will be faced in the future by the additive manufacturing industry?
To stay up to date with the latest 3D printing news, don’t forget to subscribe to the 3D Printing Industry Newsletter Follow us on TwitterLike our page or send us an email Facebook.
While you’re here, why not subscribe to our Youtube channel? Featuring discussion, debriefs, video shorts, and webinar replays.
Are you looking to find a job in additive manufacturing? Visit 3D Printing Jobs Here are some examples of the roles available in this industry.
This image features a representative sheet of Tissue PaperTM, which is made from ovarian tissues. It highlights the unique micro-and nano-porosity of its texture and texture. Image via DimensionInx.